KEY DETAILS
STAT reported on October 9, 2026 that a second major U.K. health body has cut ties with a Teva Pharmaceuticals unit after coming under pressure from pro-Palestine campaigners.
Gizmodo reported on October 9, 2026 that Novo Nordisk and Eli Lilly scientists presented data suggesting semaglutide and tirzepatide slowed molecular aging clocks compared with placebo. The studies have not gone through peer review and were conducted by company scientists.
Newsmax reported on October 9, 2026 that research suggests certain foods can stimulate the body's natural production of GLP-1, a hormone that helps regulate appetite and blood sugar.
MIT Technology Review asked on October 9, 2026 whether GLP-1 drugs could affect hair, nails, and vision, and said we are still figuring out the side effects.
A New York Post article from October 8, 2026 on a study linking GLP-1 use to nail disorders was already covered in an earlier edition and is not new.
STAT reported on October 9, 2026 that a second major U.K. health body has cut ties with a Teva Pharmaceuticals unit after coming under pressure from pro-Palestine campaigners. Gizmodo reported data from Novo Nordisk and Eli Lilly scientists on GLP-1 drugs and molecular aging clocks, and Newsmax reported on research into foods and natural GLP-1 production. MIT Technology Review asked what we still do not know about side effects on hair, nails, and vision.
STAT reported on October 9, 2026 that a second major U.K. health body cut ties with a Teva Pharmaceuticals unit after coming under pressure from pro-Palestine campaigners.
Gizmodo reported on October 9, 2026 that scientists from Novo Nordisk and Eli Lilly presented data showing that the GLP-1 drugs semaglutide and tirzepatide can slow molecular aging clocks by several years compared with placebo. Semaglutide users showed a reduction in aging markers of two to three years on most clocks. Both studies were presented at an anti-aging conference, have not gone through peer review, and were conducted by company scientists rather than independent researchers.
Newsmax reported on October 9, 2026 that research suggests certain foods can stimulate the body's natural production of GLP-1, a hormone that helps regulate appetite and blood sugar.
MIT Technology Review published a piece on October 9, 2026 titled "We're still figuring out the side effects of GLP-1 weight-loss drugs," which asked whether the drugs could affect hair, nails, and vision. It noted that the most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, and that the drugs have also been linked to pancreatitis and gallstone disease.
The New York Post reported on October 8, 2026 on a study of nail changes, which was already covered in an earlier edition of this newsletter and is not new. One study reported GLP-1 users were nearly 25% more likely to have a nail disorder than people not on the drugs. It also reported hair loss in 50% of GLP-1 users versus 34% of those not on the drugs.
The stories above come from reports published on October 8 and 9, 2026. The aging clock data have not been peer reviewed, and the side effect questions are still being studied.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.